Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 11 Aug 2022 |
| U.S. FDA approves additional indication of darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) | 8 Aug 2022 |
| Orion Corporation: Managers' transactions - Virve Laitinen | 5 Aug 2022 |
| Orion Group Half-Year Financial Report 1-6/2022 | 15 Jul 2022 |
| Orion Corporation's financial reporting and Annual General Meeting in 2023 | 15 Jul 2022 |